Mabuchi 1998.

Methods	4‐week dietary period 4‐week before‐and‐after study
Participants	20 men and women with heterozygous FH aged from 33‐70 years old received cerivastatin Exclusion criteria: none reported Cerivastatin 0.2 mg/d baseline TC: 8.78 mmol/L (339.6 mg/dL) Cerivastatin 0.2 mg/d baseline LDL‐C: 6.92 mmol/L (267.6 mg/dL) Cerivastatin 0.2 mg/d baseline HDL‐C: 0.99 mmol/L (38.3 mg/dL)
Interventions	Cerivastatin 0.2 mg/d Cerivastatin 0.2 mg/d + cholestyramine 8g/d Cerivastatin 0.2 mg/d + procubol 1g/d
Outcomes	Percentage change from baseline at 4 weeks of plasma TC, LDL‐C and HDL‐C
Source of funding	Unknown
Notes	Cerivastatin 0.2 mg/d associated with cholestyramine 8 g/d or procubol 1 g/d started after 4 weeks, data were not analysed. SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before‐and‐after design
Allocation concealment (selection bias)	High risk	Controlled before‐and‐after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐C	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAE	High risk	No comparison possible
Incomplete outcome data (attrition bias) Total cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) LDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) HDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) Triglycerides	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding not reported